Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 5:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pharmacokinetic Assessments in Healthy Volunteers Clear all
Not listed Phase 1 Interventional Accepts healthy volunteers

Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment

NCT04620109
View directory record Official record
Conditions
Corneal Neovascularization
Interventions
KDR2-2, Placebo
Drug
Lead sponsor
Guangzhou HuiBoRui Biological Pharmaceutical Technology Co. Ltd
Industry
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 8, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients

NCT02103426
View directory record Official record
Conditions
Dialysis, Healthy Subjects, Cytomegalovirus Infection
Interventions
ASP0113, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
4
States / cities
Los Angeles, California • Orlando, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 8, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR

NCT01192152
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
saxagliptin, Glucophage XR, saxagliptin + metformin XR (FDC tablet)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 8, 2026, 5:32 AM EDT
Completed Phase 1 Interventional

Fenretinide Mucoadhesive Patch: Evaluation of Oral Cancer Prevention Efficacy in Adults With Premalignant Oral Lesions.

NCT07149220
View directory record Official record
Conditions
Oral Leukoplakia, Oral Dysplasia
Interventions
Mucoadhesive fenretinide-releasing system (FMS)
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 100 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 8, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy Subjects

NCT03958123
View directory record Official record
Conditions
Prolonged QTc Interval, Pharmacokinetic
Interventions
100 μg cebranopadol, 200 μg cebranopadol, 400 μg cebranopadol, Placebo to cebranopadol encapsulated tablets, 400 mg Moxifloxacin, Placebo to moxifloxacin encapsulated tablets
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 8, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine

NCT01153386
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil diethanolamine
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2010 · Synced Oct 8, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Civamide Patch Safety, Tolerability and PK Study

NCT00758433
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Zucapsaicin, Placebo patch
Drug
Lead sponsor
Winston Laboratories
Industry
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Port Chester, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2011 · Synced Oct 8, 2026, 5:32 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics

NCT01188577
View directory record Official record
Conditions
Asthma, Bronchospasm, Wheezing, Shortness of Breath
Interventions
Epinephrine Inhalation Aerosol, HFA, Epinephrine Inhalation Aerosol
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 30 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 8, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Dose Escalation Trial Of PF-04308515 In Healthy Volunteers

NCT01101932
View directory record Official record
Conditions
Healthy
Interventions
PF-04308515, Placebo, PF-04308515 Tablet
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Oct 8, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Evaluation of Intranasal, Intramuscular, and Oral Naltrexone in Healthy Volunteers

NCT02750748
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Naltrexone, Intravail
Drug · Other
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 8, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic, Immunogenicity, and Safety Evaluation of Pegfilgrastim TPI-120 in Healthy Adults

NCT07416955
View directory record Official record
Conditions
Healthy Volunteer
Interventions
TPI-120 Pre-Filled Syringe 6 mg/0.6 mL
Biological
Lead sponsor
Kashiv BioSciences, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 8, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigation To Determine The Potential Interaction Effect Between GW876008 And Midazolam.

NCT00423761
View directory record Official record
Conditions
Healthy Subjects
Interventions
midazolam, GW876008
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2009 · Synced Oct 8, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of Relative Bioavailability of PPI-668 New Tablet Versus Capsule Formulations

NCT02258321
View directory record Official record
Conditions
Pharmacokinetic Assessments in Healthy Volunteers
Interventions
PPI-668 tablet, PPI-668 capsule
Drug
Lead sponsor
Presidio Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2015 · Synced Oct 8, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Evaluation of Intranasal and Intramuscular Naloxone in Healthy Volunteers

NCT02572089
View directory record Official record
Conditions
Drug Overdose, Opioid-Related Disorders
Interventions
Naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 8, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic (PK) Evaluation of Nalmefene Formulations

NCT07543276
View directory record Official record
Conditions
Opioid Overdose
Interventions
Nalmefene + 0.94% MgCl2, Nalmefene Hydrochloride Injection
Drug
Lead sponsor
Knoa Pharma LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 8, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Ketoconazole on Sufentanil NanoTab Pharmacokinetics

NCT01721070
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Sufentanil NanoTab (SUF NT) 15 mcg, Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcg
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 8, 2026, 5:32 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults

NCT01737892
View directory record Official record
Conditions
Asthma
Interventions
Arm T Epinephrine Inhalation Aerosol HFA, 125 mcg, 1 inhalation, Arm C-Epinephrine Inhalation Aerosol CFC
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 30 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 8, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Pharmacokinetics of a Single Oral Dose of EDP-788

NCT01999725
View directory record Official record
Conditions
Safety in Normal Volunteers
Interventions
EDP-788, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2015 · Synced Oct 8, 2026, 5:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Lidocaine Serum Levels in Healthy Adult Volunteers: a Pilot Evaluation of the J-Tip Delivery System

NCT01674075
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 59 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Oct 8, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Evaluation of Intranasal Nalmefene

NCT04759768
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Nalmefene Hydrochloride, Nalmefene
Drug
Lead sponsor
Opiant Pharmaceuticals Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 8, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic (PK) Study of Single-dose Rosuvastatin and Tipranavir/Ritonavir in Healthy Subjects

NCT00344123
View directory record Official record
Conditions
HIV Infections
Interventions
Tipranavir/Ritonavir, Rosuvastatin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 8, 2026, 5:32 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacokinetics (PK) Study of Epinephrine Inhalation Aerosol in Healthy Volunteers

NCT01143051
View directory record Official record
Conditions
Asthma
Interventions
epinephrine inhalation aerosol
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 30 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 8, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS

NCT01255709
View directory record Official record
Conditions
Asthma
Interventions
Arm T1: Primatene Mist HFA, Arm T2: Primatene Mist HFA, Arm C: Primatene Mist (epinephrine inhalation aerosol, USP)
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 30 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 8, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of PK of AC-1204 Mixed in Water, AC-1202 Mixed in Water, and AC-1202 Mixed in Ensure® on Ketone Body Production

NCT02959710
View directory record Official record
Conditions
Healthy
Interventions
AC-1204 mixed in water, AC-1202 mixed in water, AC-1202 mixed in Ensure®
Drug
Lead sponsor
Cerecin
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 8, 2026, 5:32 AM EDT